Skip to results

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 226 to 250 of 283

Guidance and quality standards awaiting development
TitleType
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation TSID 12009Technology appraisal guidance
Talquetamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5082]Technology appraisal guidance
Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]Technology appraisal guidance
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition [ID6259]Technology appraisal guidance
Teprotumumab for treating thyroid eye disease ID 6432Technology appraisal guidance
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918Technology appraisal guidance
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]Technology appraisal guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer TS ID 11951Technology appraisal guidance
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Technology appraisal guidance
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]Technology appraisal guidance
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome TS ID 11794Technology appraisal guidance
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683Technology appraisal guidance
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]Technology appraisal guidance
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]Technology appraisal guidance
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]Technology appraisal guidance
Tocilizumab for treating systemic sclerosis (ID1396)Technology appraisal guidance
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All